Maravai LifeSciences Holdings Inc (MRVI) Faces Net Loss in 2023 Despite Revenue Outperformance [Yahoo! Finance]
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: Yahoo! Finance
Net Loss : Recorded a net loss of $(138.4) million for the year, attributed to valuation adjustments and decreased demand. Adjusted EBITDA Margin : Achieved 23% for the full year, reflecting cost reduction efforts and operational efficiency. Product Innovation : TriLink BioTechnologies secures patents and enters supply agreement, signaling growth in the mRNA space. 2024 Revenue Guidance : Projected to be between $265.0 million to $285.0 million with an Adjusted EBITDA margin of 23% to 25%. Warning! GuruFocus has detected 3 Warning Sign with MRVI. On February 22, 2024, Maravai LifeSciences Holdings Inc ( NASDAQ:MRVI ) released its 8-K filing , detailing the financial results for the fourth quarter and full year ended December 31, 2023. The life sciences company, known for its products that enable drug therapies, diagnostics, and research on human diseases, faced a challenging year with significant revenue decline and a net loss. Financial Performance and Challenges Marav
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production [Yahoo! Finance]Yahoo! Finance
- TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionBusiness Wire
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024GlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Should You Sell Maravai LifeSciences (MRVI)? [Yahoo! Finance]Yahoo! Finance
MRVI
Earnings
- 2/22/24 - Beat
MRVI
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- 4/16/24 - Form 4
- MRVI's page on the SEC website